Home Epigenomics

Epigenomics

acquired
Post-IPO Round
Molecular Diagnostics Product Developer

Basic Information

Epigenomics AG is a molecular diagnostics company focused on early cancer detection in blood using its proprietary DNA methylation marker technology. Epigenomics' lead product, Epi proColon, is a blood screening test for diagnosing colorectal cancer, which has already received certifications from the FDA, CE, and CFDA. It is currently being promoted in the United States, Europe, China, and other countries. Another product by Epigenomics, Epi ProLung, primarily used for lung cancer blood screening, has not yet obtained market sales approval.
Epigenomics AG
Berlin,Berlin,Germany
101~500 people
January 01, 1998
contact@epigenomics.com